About SYN-120SYN-120, a potent and selective antagonist of the 5-HT6 receptor was discovered by Roche and is now in the development of Synosia for treatment of cognitive disorders over the counter ed treatment . Antagonism of 5-HT6 receptors that exclusively in the regions of the brain with cognitive, leads to an increased concentration of expressed acetylcholine and glutamate in those regions associated. In schizophrenic patientslcholinesterase inhibitors for the treatment for the treatment of Alzheimer’s. SYN-120 is expected to be more efficacious than the acetylcholinesterase inhibitor and as free of side effects of this class. From non – selective increases acetylcholine in organs other than the brain Preclinical studies in a variety of models have shown that 5-HT6 antagonists. Improve improve a reversal of cognitive losses associated with Alzheimer’s disease and executive function in schizophrenia.
He was in a lecture at the Congress of the Humanities and Social Sciences was held in Ottawa the Carleton University presented this week argues that hyperactivity as we understand it, is now a modern design, 1950s and 60s,tury. Described as a disorder in 1957.
Co Center At Yale investigate What Makes The Human Brain Uniqueuse more than $ 25 million the form of grants from to National Institutes of Health, that Yale School a new research a new research center to investigate how the brain developing uniquely human characteristics creates. The founders hope to that the center of that the center of of new treatment options for many forms of psychological diseases such schizophrenia, autism and bipolar disease.
In cooperation with the to all Institute Brain Science and of University of Southern California, Yale researchers leading Sestan be identify all Generate and non-coding transcripts control the development of human brain. IIA use advanced genomics technologies gene activity in the developing human and non – human primates for compared cerebral.